Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 7,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

NCT05223218
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Melanoma
Interventions
Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

NCT06662097
View directory record Official record
Conditions
Surgery, Nerve Injury, Imaging
Interventions
Bevonescein
Drug
Lead sponsor
Alume Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

NCT01396382
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
68Ga-DOTATATE PET scan
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 28, 2026, 10:24 AM EDT
Terminated Phase 4 Interventional

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

NCT01838174
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR Gel (ACTH), IV methylprednisolone (steroids)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

NCT07543991
View directory record Official record
Conditions
Giant Axonal Neuropathy (GAN)
Interventions
scAAV9/JeT-GAN
Genetic
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

NCT04541082
View directory record Official record
Conditions
Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor
Interventions
ONC206
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Terminated No phase listed Observational

Sample Collection From Melanoma Patients

NCT00507325
View directory record Official record
Conditions
Melanoma
Interventions
Blood Sample, Tumor Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 28, 2026, 10:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617
View directory record Official record
Conditions
Medulloblastoma
Interventions
Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine, Aerobic Training, Neurocognitive Remediation
Radiation · Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
14
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

NCT00512889
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion
Biological · Genetic · Drug + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 2 Interventional

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290
View directory record Official record
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 4 Interventional

Sub-Paraspinal Block in Nuss Patients. A Pilot Project

NCT02169297
View directory record Official record
Conditions
Pectus Excavatum, Pain, Postoperative
Interventions
Ultrasound-guided Sub-Paraspinal Block, PCA only
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 28, 2026, 10:24 AM EDT
Suspended No phase listed Observational

GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

NCT05695976
View directory record Official record
Conditions
Glioblastoma, Glioma, Malignant
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00003876
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polifeprosan 20 with carmustine implant, surgical procedure, iodine I 125
Drug · Procedure · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Terminated Phase 1 Interventional

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

NCT02337309
View directory record Official record
Conditions
Neuroblastoma
Interventions
SF1126
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Interventional Study of Effects on Spine Height With Two Unloading Positions

NCT01048749
View directory record Official record
Conditions
Low Back Pain
Interventions
aquatic vertical suspension., land-based supine flexion
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleburne, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 28, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib to Treat Recurrent Brain Cancer

NCT00923117
View directory record Official record
Conditions
Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions
Sutent (sunitinib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 28, 2026, 10:24 AM EDT
Recruiting Phase 2 Interventional

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT03412877
View directory record Official record
Conditions
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Early Phase 1 Interventional

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

NCT02490930
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
Fingolimod
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 28, 2026, 10:24 AM EDT
Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 10:24 AM EDT
Completed No phase listed Observational

Pediatric NMOSD Observational Study

NCT03766347
View directory record Official record
Conditions
Neuromyelitis Optica, NMO Spectrum Disorder
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 28, 2026, 10:24 AM EDT
Completed No phase listed Observational

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658
View directory record Official record
Conditions
Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 10:24 AM EDT